Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $734,143.86 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,947 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total value of $734,143.86. Following the completion of the sale, the insider directly owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. This represents a 20.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Joana Goncalves also recently made the following trade(s):

• On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $111.84, for a total value of $782,880.00.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA opened at $97.73 on Friday. Oruka Therapeutics, Inc. has a fifty-two week low of $14.89 and a fifty-two week high of $115.51. The stock has a market capitalization of $6.47 billion, a P/E ratio of -48.14 and a beta of -0.34. The business has a 50-day moving average of $96.24 and a two-hundred day moving average of $73.64.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, research analysts expect that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ORKA shares. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Guggenheim restated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. BTIG Research reiterated a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors have recently modified their holdings of the stock. Sei Investments Co. boosted its stake in Oruka Therapeutics by 136.0% in the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after purchasing an additional 13,164 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Oruka Therapeutics in the 1st quarter valued at about $5,543,000. Handelsbanken Fonder AB bought a new stake in shares of Oruka Therapeutics in the second quarter valued at about $15,313,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Oruka Therapeutics by 18.3% in the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after purchasing an additional 11,205 shares in the last quarter. Finally, Braidwell LP acquired a new position in shares of Oruka Therapeutics during the second quarter worth about $26,473,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.